About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker BLCO · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 10, 2026BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial
NCT07778888 · Dry Eye Disease
BL1107
BLCO
Bausch & Lomb Incorporated
Phase 2Recruiting
was not yet recruiting
20Feb 2027Registry ↗
Nov 5, 2026Evaluation of a New Laser Refractive Vision Correction Using the TENEO™ 317 Model 2
NCT06997003 · Hyperopia and Myopia
Anterior treatment mode, Anterior treatment mode
BLCO
Bausch & Lomb GmbH
Not applicableRecruiting81May 2027Registry ↗
Oct 22, 2026A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pai…
NCT07412496 · Pain, Postoperative
Topical Ocular BL1332 low dose, Topical Ocular BL1332 high…
BLCO
Bausch & Lomb Incorporated
Phase 2Completed130Oct 4, 2026Registry ↗
Oct 16, 2026Revive Toric RWE Study
NCT06785194 · Astigmatism
REVIVE samfilcon B custom toric contact lenses
BLCO
Bausch & Lomb Incorporated
—Withdrawn0Mar 2026Registry ↗
Oct 8, 2026Safety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for Laser In Situ Keratom…
NCT05264623 · Hyperopia
TENEO 317 Model 2 excimer laser
BLCO
Bausch & Lomb Incorporated
Not applicableCompleted140Aug 24, 2026Registry ↗
Sep 17, 20261-Week Dispensing Evaluation of Kalifilcon A Toric Contact Lenses Compared to Ultra for Astigmatism
NCT05320042 · Myopia, Astigmatism
kalifilcon A daily disposable toric contact lenses, Ultra f…
BLCO
Bausch & Lomb Incorporated
Not applicableCompleted35May 10, 2022Registry ↗
Sep 10, 2026A Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Trial Participants
NCT07717918 · Healthy
BL1332 eye drops, BL1332 Placebo eye drops
BLCO
Bausch & Lomb Incorporated
Phase 1Completed28Aug 5, 2026Registry ↗
Aug 25, 20261-Week Dispensing Evaluation of REVIVE™ Toric Soft Contact Lenses
NCT06053736 · Refractive Ametropia, Astigmatism
REVIVE Toric Soft Contact Lenses
BLCO
Bausch & Lomb Incorporated
Not applicableCompleted32Dec 15, 2023Registry ↗
Aug 25, 2026Biotrue ONEday Contact Lenses With EPG03 Packaging Solution Compared to Biotrue ONEday Contact Lens…
NCT05129488 · Contact Lens Wearer
All participants received Biotrue ONEday lenses with and wi…
BLCO
Bausch & Lomb Incorporated
Not applicableCompleted33Sep 20, 2021Registry ↗
Aug 6, 20261-Week Dispensing Evaluation of Kalifilcon A Daily Disposable Multifocal Compared to Ultra for Pres…
NCT05325931 · Presbyopia
kalifilcon A Daily Disposable Multifocal, samfilcon A for P…
BLCO
Bausch & Lomb Incorporated
Not applicableCompleted30Mar 28, 2022Registry ↗
Aug 5, 2026Surface Refractive Index Shift of Kalifilcon A Compared With Dailies Total1 and Precision1 Lenses
NCT04840563 · Contact Lens Wear
kalifilcon A daily disposable spherical soft contact lens,…
BLCO
Bausch & Lomb Incorporated
Not applicableCompleted10Apr 15, 2021Registry ↗
Jul 22, 2026Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular…
NCT07168902 · Glaucoma
BL1107 Low dose, BL1107 High dose
BLCO
Bausch & Lomb Incorporated
Phase 2Completed252May 18, 2026Registry ↗
Jul 14, 2026A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
NCT07128628 · Dry Eye Disease
Lifitegrast/Perfluorohexyloctane Fixed Dose Combination, Li…
BLCO
Bausch & Lomb Incorporated
Phase 2Completed443May 28, 2026Registry ↗
Jul 13, 2026Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF Intraocular Lens in…
NCT06333015 · Cataract
enVista Beyond EY (EDF) IOL, enVista MX60E monofocal IOL
BLCO
Bausch & Lomb Incorporated
Not applicableCompleted304Jun 11, 2026Registry ↗
Jul 6, 2026A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Ref…
NCT06346340 · Dry Eye
Miebo
BLCO
Bausch & Lomb Incorporated
Phase 4Completed97Feb 24, 2025Registry ↗
Jun 3, 2026A Study to Evaluate Real World Outcomes of the enVista® Aspire (EA) and Aspire Toric (ETA) Intraocu…
NCT06594185 · Cataract
enVista Aspire EA or Aspire Toric ETA IOLs
BLCO
Bausch & Lomb Incorporated
Not applicableCompleted335May 21, 2025Registry ↗
May 28, 2026A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With S…
NCT06803654 · Ocular Redness
BTOS-HA, Lumify®
BLCO
Bausch & Lomb Incorporated
Phase 3Completed578Jun 29, 2025Registry ↗
May 26, 2026Clinical Evaluation of the Performance of the enVista® Aspire™ (EA) Lens
NCT06479148 · Cataract
enVista® Aspire™, An IOL with a slightly extended depth of…
BLCO
Bausch & Lomb Incorporated
Not applicableTerminated27Dec 12, 2024Registry ↗
May 6, 2026A Post-Market Clinical Follow-Up on Safety and Performance of the Ophthalmic Viscoelastic Devices E…
NCT06767917 · Cataract
Eyefill® S.C., Eyefill® M.B.
BLCO
Bausch & Lomb GmbH
Not applicableCompleted148Mar 25, 2026Registry ↗
Jan 30, 2026A Study to Investigate the Safety and Effectiveness of the Technolas® TENEO 317 Model 2 Excimer Las…
NCT07377474 · Myopic Astigmatism
TENEO 317 Model 2 (1.28 US) Excimer Laser
BLCO
Bausch & Lomb Incorporated
Not applicableNot yet recruiting32Sep 2027Registry ↗
Jan 27, 2026A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical…
NCT06978244 · Ocular Pain
BL1332 ophthalmic solution, BL1332 ophthalmic vehicle
BLCO
Bausch & Lomb Incorporated
Phase 1Active, not recruiting24Nov 2026Registry ↗
Jan 12, 2026IC-8 Apthera IOL New Enrollment Post Approval Study
NCT06060041 · Cataract, Presbyopia
BLCO
Bausch & Lomb Incorporated
—Recruiting435Sep 30, 2027Registry ↗
Dec 18, 2025A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear
NCT07054606 · Dry Eye
Perfluorohexyloctane ophthalmic solution
BLCO
Bausch & Lomb Incorporated
Phase 4Completed104Nov 3, 2025Registry ↗
Dec 10, 2025A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination i…
NCT07111013 · Dry Eye Disease
Lifitegrast/perfluorohexyloctane (PFHO)
BLCO
Bausch & Lomb Incorporated
Phase 3Withdrawn0Apr 2027Registry ↗
Oct 21, 2025A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease
NCT06309953 · Dry Eye
Miebo
BLCO
Bausch & Lomb Incorporated
Phase 4Completed99Jun 17, 2024Registry ↗
Aug 24, 2025Study of Safety and Effectiveness of the Boston Orthokeratology Shaping Lens in the Arise Orthokera…
NCT05984290 · Myopia
orthokeratology lens
BLCO
Bausch & Lomb Incorporated
Not applicableCompleted90Jun 27, 2024Registry ↗
Jul 20, 20252-Hour Dispensing Evaluation of Samfilcon A Lenses With EPG01 Packaging Solution Compared to Commer…
NCT05126953 · Contact Lens Wearer
samfilcon A Lenses with EPG01 Packaging Solution, Commercia…
BLCO
Bausch & Lomb Incorporated
Not applicableCompleted30Sep 23, 2021Registry ↗
Jul 10, 2025Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.0…
NCT05815758 · Allergic Conjunctivitis
Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophth…
BLCO
Bausch & Lomb Incorporated
Phase 3Completed512Sep 18, 2023Registry ↗
Jul 10, 2025Insertion Clinical Study to Evaluate the Orientation Characteristics of Multiple Kalifilcon A Daily…
NCT05129124 · Astigmatism
kalifilcon A Daily Disposable Toric LD213001 Contact Lenses…
BLCO
Bausch & Lomb Incorporated
Not applicableCompleted30Jan 13, 2022Registry ↗
Jul 4, 2025Effects of NOV03 on the Tear Film
NCT05723770 · Dry Eye Disease (DED)
instillation of NOV03
BLCO
Bausch & Lomb Incorporated
Phase 4Completed33Dec 23, 2023Registry ↗
Jul 1, 2025Orientation Characteristics of Daily Disposable Toric Contact Lenses
NCT06069609 · Astigmatism
kalifilcon A Daily Disposable Toric, Acuvue Oasys 1-Day for…
BLCO
Bausch & Lomb Incorporated
Not applicableCompleted30Aug 15, 2023Registry ↗
Jul 1, 2025Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic…
NCT05591755 · Seasonal Allergic Conjunctivitis
Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Opht…
BLCO
Bausch & Lomb Incorporated
Phase 3Completed229Aug 9, 2023Registry ↗
Jun 24, 2025Insertion Clinical Study to Evaluate the Aberration Characteristics of Kalifilcon A Toric Lenses
NCT05129072 · Contact Lens Wearer
kalifilcon A Daily Disposable Toric LD213001 lens in SKUs +…
BLCO
Bausch & Lomb Incorporated
Not applicableCompleted75Sep 24, 2021Registry ↗
Jun 15, 2025Effectiveness and Safety of the TENEO 317 Model 2 Excimer Laser to Treat Myopia With or Without Ast…
NCT06618547 · Myopia
TENEO 317 Model 2 excimer laser
BLCO
Bausch & Lomb Incorporated
Not applicableNot yet recruiting140Nov 2026Registry ↗
Jun 15, 2025A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correc…
NCT06305663 · Myopia
Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophil…
BLCO
Bausch & Lomb Incorporated
Not applicableRecruiting418Jan 31, 2027Registry ↗
May 20, 2025A Study to Evaluate the Safety and Effectiveness of a Contact Lens Cleaning and Disinfecting Soluti…
NCT05565937 · Refractive Ametropia
BL-3100-NBR03 multi-purpose solution, renu® Advanced Formul…
BLCO
Bausch & Lomb Incorporated
Not applicableCompleted295Feb 28, 2024Registry ↗
May 2, 2025A Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract Extra…
NCT06333028 · Cataract
enVista Aspire EA IOLs
BLCO
Bausch & Lomb Incorporated
—Completed82Mar 13, 2025Registry ↗
Mar 27, 2025Safety and IOP-Lowering Effects of WB007
NCT04149899 · Glaucoma, Primary Open Angle, Ocular Hypertension
WB007 0.05%, WB007 0.15%
BLCO
Bausch & Lomb Incorporated
Phase 1/2Completed77Jan 31, 2021Registry ↗
Feb 14, 2025Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Con…
NCT05579730 · Allergic Conjunctivitis
Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%, Brim…
BLCO
Bausch & Lomb Incorporated
Phase 3Completed188Jul 22, 2023Registry ↗
Dec 24, 2024Evaluate the Safety and Effectiveness of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intrao…
NCT03603600 · Cataract
enVista MX60E, enVista MX60EF
BLCO
Bausch & Lomb Incorporated
Not applicableCompleted501May 4, 2023Registry ↗
Dec 17, 2024A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) A…
NCT06565650 · Dry Eye
Miebo, Saline
BLCO
Bausch & Lomb Incorporated
Phase 4Active, not recruiting216Nov 2025Registry ↗
Dec 10, 2024Kalifilcon A Toric Compared to Commercially Available Lenses
NCT06098937 · Astigmatism
Kalifilcon Toric Lens, Total1 for Astigmatism
BLCO
Bausch & Lomb Incorporated
Not applicableCompleted30Sep 27, 2023Registry ↗
Oct 23, 2024Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated…
NCT04139798 · Dry Eye Disease (DED)
NOV03, Placebo
BLCO
Bausch & Lomb Incorporated
Phase 3Completed599Mar 12, 2021Registry ↗
Oct 10, 2024Clinical Study to Evaluate the Safety and Performance of the enVista® One-Piece Hydrophobic Acrylic…
NCT04224155 · Cataract
enVista MX60EFH trifocal intraocular lenses (IOLs), enVista…
BLCO
Bausch & Lomb Incorporated
Not applicableCompleted165Jun 14, 2022Registry ↗
Oct 8, 2024Evaluation of Ocular Comfort With ISTA Tears vs Systane
NCT01650584 · Dry Eye Disease
ISTA Tears, Systane
BLCO
Bausch & Lomb Incorporated
Not applicableCompleted35Dec 2012Registry ↗
Aug 26, 2024"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Re…
NCT05360784 · Ocular Redness
Brimonidine tartrate ophthalmic solution 0.025% preservativ…
BLCO
Bausch & Lomb Incorporated
Phase 3Completed380Nov 23, 2022Registry ↗
Aug 19, 2024Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunctio…
NCT04567329 · Dry Eye Disease
NOV03, Saline Solution
BLCO
Bausch & Lomb Incorporated
Phase 3Completed620Aug 30, 2021Registry ↗
Jul 10, 2024A Safety and Effectiveness Study of a New Preservative Free Rewetting Drop
NCT04175340 · Contact Lens Wear
BL-300-PFM04, OPTI-FREE
BLCO
Bausch & Lomb Incorporated
Not applicableCompleted369Feb 17, 2020Registry ↗
Jun 14, 2024A Study With Technolas® TENEO 317 Model 2 Excimer Laser to Treat Participants With Myopia or Myopic…
NCT04111757 · Myopia, Myopic Astigmatism
Technolas® TENEO 317 Model 2
BLCO
Bausch & Lomb Incorporated
Not applicableCompleted168Aug 6, 2021Registry ↗
May 28, 2024A Study of B + L Ophthalmic Viscosurgical Device (OVD) CVisc50
NCT04192630 · Cataract
CVisc50 OVD, ProVisc OVD
BLCO
Bausch & Lomb Incorporated
Not applicableCompleted390Jan 31, 2022Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:08 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances